BLFS vs CYRX
BLFS: BioLife Solutions develops biopreservation media and cell processing products designed to improve quality and reduce risk in cell and gene therapy manufacturing and distribution. CYRX: Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization.
Side-by-side fundamentals
| Metric | BLFS | CYRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $31.15 | $16.42 | |
| Market cap as of 2026-07-23 | $1.4B | $838M | |
| P/E as of 2026-07-23 | n/a | 11.02 | |
| PEG as of 2026-07-23 | -0.20 | n/a | |
| Net margin as of 2026-07-23 | -3.0% | +41.6% | CYRX higher |
| Gross margin as of 2026-07-23 | +64.0% | +47.2% | BLFS higher |
| Operating margin as of 2026-07-23 | -15.4% | -21.4% | BLFS higher |
| ROE as of 2026-07-23 | -0.8% | +15.0% | CYRX higher |
| ROA as of 2026-07-23 | -0.8% | +9.9% | CYRX higher |
| Debt / equity as of 2026-07-23 | 0.01 | 0.38 | BLFS lower |
| Revenue growth (YoY) as of 2026-07-23 | +25.6% | -14.8% | BLFS higher |
| Revenue CAGR (3y) SEC XBRL | +30.9% | -9.4% | BLFS higher |
| Beta as of 2026-07-23 | 1.92 | 1.89 | |
| 1-year return as of 2026-07-22 close | +40.6% | +121.0% | CYRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.